Cancer Research Landon Prizes for Basic and Translational Cancer Research AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendoza, N.
Right arrow Articles by Wickramasinghe, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendoza, N.
Right arrow Articles by Wickramasinghe, D.
[Cancer Research 63, 1020-1024, March 1, 2003]
© 2003 American Association for Cancer Research

Experimental Therapeutics

Selective Cyclin-dependent Kinase 2/Cyclin A Antagonists that Differ from ATP Site Inhibitors Block Tumor Growth

Nerissa Mendoza, Sharon Fong, Jim Marsters, Hartmut Koeppen, Ralph Schwall and Dineli Wickramasinghe1

Departments of Molecular Oncology [N. M., S. F., R. S., D. W.], Bioorganic Chemistry [J. M.], and Pathology [H. K.], Genentech, Inc., South San Francisco, California 94080

A central function of the tumor suppressor retinoblastoma (Rb) is its ability to repress E2F transcriptional activity. Many cancers harbor inactivated Rb and consequently deregulated E2F. RXL peptides inhibit E2F recruitment and phosphorylation by CDK2/cyclin A. Here we report that RXL peptides selectively kill tumor cells with deregulated Rb/cyclin D pathways. We extend these observations to tumor models and demonstrate inhibition of tumor growth in SV40 large T transformed Balb/c 3T3 grafts and in HER2 transgenic tumors. Moreover, our observations reveal that RXL peptide-treated tumors undergo apoptosis. Our results indicate that RXL motif-based inhibitors will provide selective antiproliferative agents with in vivo efficacy in tumors with deregulated Rb/cyclin D pathways.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
N. Canela, M. Orzaez, R. Fucho, F. Mateo, R. Gutierrez, A. Pineda-Lucena, O. Bachs, and E. Perez-Paya
Identification of an Hexapeptide That Binds to a Surface Pocket in Cyclin A and Inhibits the Catalytic Activity of the Complex Cyclin-dependent Kinase 2-Cyclin A
J. Biol. Chem., November 24, 2006; 281(47): 35942 - 35953.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. DePinto, X.-J. Chu, X. Yin, M. Smith, K. Packman, P. Goelzer, A. Lovey, Y. Chen, H. Qian, R. Hamid, et al.
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
Mol. Cancer Ther., November 1, 2006; 5(11): 2644 - 2658.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K.-Y. Cheng, M. E. M. Noble, V. Skamnaki, N. R. Brown, E. D. Lowe, L. Kontogiannis, K. Shen, P. A. Cole, G. Siligardi, and L. N. Johnson
The Role of the Phospho-CDK2/Cyclin A Recruitment Site in Substrate Recognition
J. Biol. Chem., August 11, 2006; 281(32): 23167 - 23179.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. I. Shapiro
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
J. Clin. Oncol., April 10, 2006; 24(11): 1770 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Wang, C. J. Li, P. V. Reddy, and A. B. Pardee
Cancer Chemotherapy by Deoxynucleotide Depletion and E2F-1 Elevation
Cancer Res., September 1, 2005; 65(17): 7809 - 7814.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. I. Raynaud, S. R. Whittaker, P. M. Fischer, S. McClue, M. I. Walton, S. E. Barrie, M. D. Garrett, P. Rogers, S. J. Clarke, L. R. Kelland, et al.
In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202
Clin. Cancer Res., July 1, 2005; 11(13): 4875 - 4887.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Gondeau, S. Gerbal-Chaloin, P. Bello, G. Aldrian-Herrada, M. C. Morris, and G. Divita
Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation
J. Biol. Chem., April 8, 2005; 280(14): 13793 - 13800.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Chen, J. Lee, S. Y. Cho, and H. A. Fine
Proteasome-Mediated Destruction of the Cyclin A/Cyclin-Dependent Kinase 2 Complex Suppresses Tumor Cell Growth in Vitro and in Vivo
Cancer Res., June 1, 2004; 64(11): 3949 - 3957.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. R. Whittaker, M. I. Walton, M. D. Garrett, and P. Workman
The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway
Cancer Res., January 1, 2004; 64(1): 262 - 272.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.